vigencell ema
Scope
Date
~
-
Bio & Pharma
ViGenCell obtains approval for HLA-B5801 genetic diagnostic kit for adverse reactions to gout treatment
ViGenCell, a company specializing in immunotherapy, announced on Friday that it has obtained approval from the Ministry of Food and Drug Safety (MFD...
Oct 25, 2024 (Gmt+09:00)
-
Energy
LS Eco Energy to supply UHV cables to Singapore's EMA
South Korea's LS Eco Energy Ltd. announced on Tuesday that its Vietnamese production subsidiary, LS-VINA, will supply 12 billion won ($8.99 million)...
Mar 05, 2024 (Gmt+09:00)
-
Bio & Pharma
ViGenCell, NK/T cell lymphoma treatment ‘VT-EBV-N’ designated as orphan drug in Europe
ViGenCell, a company specializing in immune cell therapy, announced on the 19th that its NK/T cell lymphoma treatment "VT-EBV-N" has been designated...
Dec 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in Europe for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...
Nov 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
Latest News
- 1 TheBorn Korea eyes M&As, overseas expansion after planned $73.7 million IPO
- 2 Korea's Hana Bank to promote foreigners as managers in overseas units
- 3 Samsung to unveil 400-layer bonding vertical NAND for AI servers by 2026
- 4 Korean LPs sharpen focus on GPs' post-investment management
- 5 LG Energy Q3 profit more than doubles on higher sales